Patients with prostate cancer continue to have excess mortality up to 15 years after diagnosis

BJU International

Volumn 114, Issue 5, 2014, Pages 691-697

  Husson, Olga ^a,c   Van Steenbergen, Liza N ^a   Koldewijn, Evert L ^b   Poortmans, Philip M ^d   Coebergh, Jan Willem W ^a,e   Janssen Heijnen, Maryska L G ^f  

^a Eindhoven Cancer Registry   (Netherlands)

^b CATHARINA HOSPITAL   (Netherlands)

^c TILBURG UNIVERSITY   (Netherlands)

^d Institute Verbeeten   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f VIECURI MEDICAL CENTER   (Netherlands)

Author keywords

cancer registry; conditional survival; long term prognosis; population based; prostate cancer

Indexed keywords

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CANCER SURVIVOR; CANCER THERAPY; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PROSTATE CANCER; SURVIVAL RATE; SURVIVAL TIME; TREATMENT PLANNING; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; PROGNOSIS; PROSTATIC NEOPLASMS; REGISTER; SURVIVAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PROGNOSIS; PROSTATIC NEOPLASMS; REGISTRIES; SURVIVAL ANALYSIS;

EID: 84912525229     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12519     Document Type: Article

References (30)

1. Neppl-Huber C, Zappa M, Coebergh JW, et al. Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths. Ann Oncol 2012; 23: 1325-1334
2. Cremers RG, Karim-Kos HE, Houterman S, et al. Prostate cancer: trends in incidence, survival and mortality in the Netherlands, 1989-2006. Eur J Cancer 2010; 46: 2077-2087
3. Janssen-Heijnen ML, Houterman S, Lemmens VE, Brenner H, Steyerberg EW, Coebergh JW,. Prognosis for long-term survivors of cancer. Ann Oncol 2007; 18: 1408-1413
4. Baade PD, Youlden DR, Chambers SK,. When do I know I am cured? Using conditional estimates to provide better information about cancer survival prospects. Med J Aust 2011; 194: 73-77
5. Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology, 3rd edn. Geneva: World Health Organisation, 2000
6. UICC. TNM Classification of Malignant Tumours, 6th edn. New York: Wiley-Liss, 2002
7. Ederer F, Heise H,. Instructions to IBM 650 Programmers in Processing Survival Computations. Bethesda MD: National Cancer Institute, 1959
8. Brenner H, Gefeller O,. An alternative approach to monitoring cancer patient survival. Cancer 1996; 78: 2004-2010
9. Brenner H, Hakulinen T,. Up-to-date long-term survival curves of patients with cancer by period analysis. J Clin Oncol 2002; 20: 826-832
10. Houterman S, Janssen-Heijnen ML, van de Poll-Franse LV, Brenner H, Coebergh JW,. Higher long-term cancer survival rates in southeastern Netherlands using up-to-date period analysis. Ann Oncol 2006; 17: 709-712
11. Brenner H, Rachet B,. Hybrid analysis for up-to-date long-term survival rates in cancer registries with delayed recording of incident cases. Eur J Cancer 2004; 40: 2494-2501
12. Brenner H, Hakulinen T,. Up-to-date and precise estimates of cancer patient survival: model-based period analysis. Am J Epidemiol 2006; 164: 689-696
13. Merrill RM, Hunter BD,. Conditional survival among cancer patients in the United States. Oncologist 2010; 15: 873-882
14. Ellison LF, Bryant H, Lockwood G, Shack L,. Conditional survival analyses across cancer sites. Health Rep 2011; 22: 21-25
15. Yu XQ, Baade PD, O'Connell DL,. Conditional survival of cancer patients: an Australian perspective. BMC Cancer 2012; 12: 460
16. Janssen-Heijnen ML, Gondos A, Bray F, et al. Clinical relevance of conditional survival of cancer patients in europe: age-specific analyses of 13 cancers. J Clin Oncol 2010; 28: 2520-2528
17. Thorstenson A, Bratt O, Akre O, et al. Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe Sweden. Eur J Cancer 2012; 48: 1672-1681
18. Van Hemelrijck M, Garmo H, Holmberg L, et al. Thromboembolic events following surgery for prostate cancer. Eur Urol 2013; 63: 354-363
19. Quinten C, Coens C, Mauer M, et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 2009; 10: 865-871
20. Mols F, Korfage IJ, Vingerhoets AJ, et al. Bowel, urinary, and sexual problems among long-term prostate cancer survivors: a population-based study. Int J Radiat Oncol Biol Phys 2009; 73: 30-38
21. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009; 101: 374-383
22. Welch HG, Albertsen PC,. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009; 101: 1325-1329
23. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL,. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008; 148: 435-448
24. Carlsson S, Sandin F, Fall K, et al. Risk of suicide in men with low-risk prostate cancer. Eur J Cancer 2013; 49: 1588-1599
25. Riihimaki M, Thomsen H, Brandt A, Sundquist J, Hemminki K,. What do prostate cancer patients die of? Oncologist 2011; 16: 175-181
26. Jespersen CG, Norgaard M, Bjerklund Johansen TE, Sogaard M, Borre M,. The influence of cardiovascular morbidity on the prognosis in prostate cancer. Experience from a 12-year nationwide Danish population-based cohort study. BMC Cancer 2011; 11: 519
27. Berglund A, Garmo H, Tishelman C, Holmberg L, Stattin P, Lambe M,. Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. J Urol 2011; 185: 833-839
28. Hoffman KE,. Management of older men with clinically localized prostate cancer: the significance of advanced age and comorbidity. Semin Radiat Oncol 2012; 22: 284-294
29. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-439
30. Eloranta S, Adolfsson J, Lambert PC, et al. How can we make cancer survival statistics more useful for patients and clinicians: an illustration using localized prostate cancer in Sweden. Cancer Causes Control 2013; 24: 505-515